Cytomx Therapeutics, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report, dated June 13, 2018, details the results of Cytomx Therapeutics, Inc.'s 2018 Annual Meeting of Stockholders. The Company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and voting results.
Material Changes and Voting Results
On the April 23, 2018 record date, 38,916,123 shares of common stock were outstanding. A total of 31,323,505 shares were voted at the Annual Meeting. Two proposals were presented:
- Proposal 1: Election of Class III Directors
- Charles S. Fuchs, M.D., M.P.H.: Elected with 26,393,613 votes for, 205,059 against, and 14,264 abstentions.
- Hoyoung Huh, M.D., Ph.D.: Elected with 20,791,734 votes for, 5,740,223 against, and 80,979 abstentions.
- Both nominees will serve until the 2021 Annual Meeting.
- Proposal 2: Ratification of Independent Auditor
- Stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2018.
- Votes: 31,214,806 for, 106,350 against, and 2,349 abstentions.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management commentary on future outlook, specific risks, contingencies, or unusual items beyond the standard voting disclosures.
Investor Verification Checklist
- Verify the full text of the Definitive Proxy Statement on Schedule 14A filed on April 26, 2018, for detailed biographies of the elected directors and the rationale for the auditor selection.
- Confirm the total number of broker non-votes (4,710,569) associated with the director election and their impact on future governance.
- Review the Company's most recent 10-K or 10-Q filings for financial performance data, as this 8-K contains no financial metrics.